Porustobart not checked
Solstice Oncology, Inc. · HBM4003
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- How it’s given
- “Administered to: Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab”In the company’s words, NCT07808151 on ClinicalTrials.gov
- Tested for
- Colon Cancer
- Main trialPhase 2
- “The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to…”In the company’s words, NCT07808151 on ClinicalTrials.gov
- Other names
- HBM4003
Other drugs for Colon Cancer
- DostarlimabGSK · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
- XLJDOD compound granuleJiangsu Famous Medical Technology Co., Ltd. · Phase 3
- RC148RemeGen · AbbVie · Phase 2/3
- INCA33890Incyte Corporation · Phase 3
- CalderasibMerck & Co. · Phase 3
Coming up1
- 30 Sep 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Sep 2029 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026